Real-world data on benralizumab for severe asthma: what happens outside clinical trials?
NCT ID NCT07218172
First seen Jun 24, 2026 · Last updated Sep 18, 2026 · Updated 3 times
Summary
This study looks back at medical records of 197 adults in Israel who started benralizumab for severe asthma between 2019 and 2024. Researchers will count how many asthma attacks (exacerbations) patients had before and after starting the drug. The goal is to see how well benralizumab works in everyday practice, not just in controlled studies.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- benralizumab
- What this could lead to
- If successful, this study could provide real-world evidence on how well benralizumab controls severe asthma in routine practice.
- What could go wrong
- This is an observational study, not a controlled trial, so results may be influenced by other factors and cannot prove cause and effect.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 197 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Mar 2025
- Expected to finish
-
Nov 2026
An estimate. End dates often move.
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
adult patients who initiated benralizumab treatment for SEA between January 1, 2019, and March 31, 2024. The study population will include both biologic-naive and biologic-experienced patients
- Ages
-
Children (under 18), adults (18 to 64) and older adults (65 and over)
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * An authorization from MHS drugs authorization center for benralizumab, with a diagnosis of asthma (ICD-9 code 493.X and the corresponding internal MHS diagnosis codes for SA). Having an authorization indicates that patients have severe eosinophilic asthma and fulfil the GINA definition of severe asthma as well as additional local reimbursement criteria. * At least one purchase of benralizumab for the first time between January 1 2019 and March 31 2024. * Age ≥18 years on the index date. * MHS members for at least 12 months before the index date. Exclusion Criteria: • Patients who received benralizumab for indication other than asthma according to MHS drugs authorization center. \- currently or recently included in a clinical trial according to the ICD-9 diagnosis code V70.7) and the corresponding internal MHS codes
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Severe asthma are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Research Site
Tel Aviv, Israel
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can an injected biologic cut steroid Flare-Ups in a Tough-to-Treat asthma complication?
- Can a single injection tame severe asthma in fungal allergy?
- Could a simple exercise programme boost asthma remission?
- A two-step strategy: biologic drug may pave the way for immunotherapy in severe olive pollen asthma
- Could a biologic drug free severe asthma patients from High-Dose steroids?
- Beyond breathing: could an asthma drug lift emotional burdens for patients and partners?